TB Research

Hypersensitivity reaction with multi-organ failure following re-exposure to rifampicin: case report and review of the literature including WHO spontaneous safety reports

Lisa Brockhaus, Yasmin Schmid, Anna Christina Rast, Alexandra E. Rätz Bravo, Kathrin Scherer Hofmeier, Anne Leuppi-Taegtmeyer

BMC Pharmacology and Toxicology · 2019-02

Abstract

BACKGROUND: True hypersensitivity reactions to rifampicin are relatively rare, nonetheless severe manifestations mostly involving a single organ have been documented. We report a case of acute multi-organ failure occurring after a medication error with re-exposure to rifampicin. CASE PRESENTATION: A 68-year old patient developed acute hypersensitivity pneumonitis, acute renal failure, acute liver failure and haemolytic anemia within hours after a second re-exposure to Rifampicin for the treatment of a hip prosthesis infection with Staphylococcus epidermidis. A recent rifampicin exposure 1 week earlier had resulted in a massive rise of CRP levels without organ manifestations. Nine years previously, the patient had developed a multi-organ hypersensitivity reaction 8 days after commencing treatment with rifampicin for pulmonary tuberculosis; and 23 years previously he had received rifampicin without problems. The organ-specific hypersensitivity reactions were largely reversible after withdrawal of rifampicin and treatment with steroids. A review of the literature and summary of WHO spontaneous safety reports is also given. CONCLUSIONS: Re-exposure to rifampicin in sensitised individuals may cause acute severe hypersensitivity reactions. Due to its indications in the management of mycobacterial and implant-associated infections, rifampicin is a drug which might be given decades apart, which poses a risk that information about previous intolerance is lost.

MeSH terms

  • Rifampicin
  • Medicine
  • Hypersensitivity pneumonitis
  • Tuberculosis
  • Intensive care medicine
  • Hypersensitivity reaction
  • Surgery
  • Internal medicine